[Registration of 30 026 cases of Shenqi Fuzheng injection combined with other drugs in real world].

Prospective, multi-center, large-sample and registered design was used to analyze the drug combination features of Shenqi Fuzheng injection in the real world clinical application, and comprehend the drug combination in the real world. A total of 30 026 patients with the use of Shenqi Fuzheng injection were registered, where the chemical drugs were used for 57 436 times (accounting for 82.76%), and the Chinese patent medicines were used for 11 962 times (accounting for 17.

[Analysis of the allergic reaction types of Chinese medicine injection based on immunotoxicty].

The purpose of the study is to find the allergic reaction types and characteristics of Chinese medicine injection ( CMI). The authors monitored patients who used Shuxuetong injection, Dengzhan Xixin injection, Shenqi Fuzheng injection, Shenmai injection, Ciwujia injection, Shuxuening injection, Tanreqing injection, Reduning injection, a total of 150,000 cases were monitored. They used a nested case-control design to group the patients and obtained the serum samples from 14 allergic patients and 55 matched patients.

[Post-marketing clinical safety assessment of Shenmai injection based on active monitoring and passive monitoring in large data background].

This paper adopted a series of related analysis methods to comprehensively analyze post-marketing clinical safety data of Shenmai injection from 4,220 cases of SRS and 32,358 cases of multicenter, prospective, registered hospital centralized monitoring in large data background, calculated ADR incidence rate was 0.93 per 1,000, main symptoms of ADR includes chest pain, chills, skin itching, palpitations, fever, nausea, dizziness, vomiting, flushing, numbness, allergic reaction, cyanosis, rash, low back pain, and "breath", "anaphylactoid reaction" and "flush" were the safety warning signals of Shenmai injection. Primary disease for chronic pulmonary heart disease, thyroid disease, and combined with cerebral vascular disease, prior to the injection and continuous use of alprostadil, cyclic adenosine monophosphate, combined with quinolones, penicillins were suspicious influence factors of ADR of Shenmai injection, these promot the clinical safety.

[Clinical safety studies based on 30 026 post-marketing cases of Shenqi Fuzheng injection by intensive hospital monitoring nested NCCS].

This study adopted a large sample, multicenter, registered hospital centralized monitoring nested prospective case-control study design. From the real world clinical application of Shenqi Fuzheng injection, monitored 30 026 cases of patients with the use of Shenqi Fuzheng injection. A total of 51 adverse drug reaction (ADR) cases was monitored, including 1 case of severe adverse reactions.

[Study of post marketing safety reevaluation of shenqi fuzheng injection].

In order to promote the Shenqifuzheng injection (SQFZ) clinical medication safety, this study reevaluate on SQFZ post marketing safety study systematically. Including multi center large sample registration type safety monitoring research, the analysis based on national spontaneous reporting system data, the analysis based on the 20 national hospital information system data and literature research. Above the analysis, it suggests that SQFZ has good security.

[Impact analysis of shenqi fuzheng injection of course on liver function based on hospital information system data].

Objective: Use propensity score methods to explore the effect of Shenqi Fuzheng injection (SQFZ) on ALT and AST lever of real worlds.

Method: HIS data from 18 hospitals was analyzed. Patients ranging from 18 to 80 years, it were divided into the cases group was used Shenqi Fuzheng injection > 21 days under the instruction, and control group used SQFZ ≤ 21 days.

[Analysis of kudiezi injection different dosage impact on patient's liver and kidney function based on hospital information system].

This study aims to explore the impact on patient's liver and kidney function by different dosage of Kudiezi injection. This study retrospectively analyzed 15 228 patients' records from 18 nationwide general hospital information system (HIS). All patients were treated with Kudiezi injection, 1 956 patients that were given doses of > 40 mL, which is above the recommended dose, acted as the observation group.

[Analysis suspected allergic factors to shenqi fuzheng injection based on prescription sequence analysis and nested case control study].

This study based on twenty 3A grade hospital information system (HIS) database in China, adopt toprescription sequence analysis (PSA) with nested case control study (NCCS) to analysis mainly suspected allergy factor of Shenqi Fuzheng injection (Shenqi Fuzheng). Study design according to start to stop using Shenqi Fuzheng whether using dexamethasone injection will crowd divided into cases group and control group, each case matched 4 controls were selected, two groups according to the ratio of the age and sex matched well. Square test, Fisher exact test, single factor and multiple factor logistic regression were used to analyze data Condition on admission, allergic history, dosage and drug combinations were taken into account in cases of suspected allergic reactions.

[Analysis of questionable allergic factors to kudiezi injection--nested case control study using hospital information system data].

This study aims to assess if adverse drug reactions (ADRs) to Kudiezi injection are allergic in origin. Hospital information system (HIS) data from 18 hospitals in China were used to carry out a nested case control design study. Included were patients who received dexamethasone for suspected allergic reactions after receiving Kudiezi injection.

[Preliminary study on integration of traditional Chinese medicine and western medicine in patients with coronary heart disease in real world].

Objective: Observe and analyze the informations of western medicine and traditional Chinese medicine in patients with coronary heart disease (CHD), in order to provide reference for clinical treatment.

Method: Select patients with CHD in diagnosis of the first place in 17 hospitals, drug informations of these patients were analyzed using frequency method and association rules.

Result: In 84 697 patients,there were 47 564 males and 32 882 females.

[Parenterally administered shenqi fuzheng for heart failure: a systematic review and meta-analysis].

Objective: To assess the efficacy and safety of parenterally administered Shenqi Fuzheng for heart failure.

Method: We searched for all clinical studies, up to February 2013, of parenterally administered Shenqi Fuzheng in the Cochrane library, Medline, EMbase, CBM, CNKI, VIP and Wanfang. Quality assessment and information extraction was completed and screened by two independent reviewers.

[Adverse drug reactions case reports for parenterally administered shuxuening based on analysis of literature].

Parenterally administered Shuxuening had made important contributions in the treatment of ischemic cardiovascular and cerebrovascular diseases since its use in 1995. Parenterally administered Shuxuening is widely used in clinical practice hence concern over its safety has gradually arisen. Based on published adverse drug reaction (ADR) case reports, this article analyzes cpatient characteristics and other data including: gender, age, history of allergies, primary disease, dose, treatment course, solvent, ADR occurrence and time scales.

[Effects of parenterally administered shenqi fuzheng on patient outcomes with tumor using propensity score].

Objective: Use propensity score methods to explore the effect of parenterally administered Shenqi Fuzheng on clinical outcome of patients with tumor.

Method: HIS data from 20 hospitals was analyzed. Patients suffering from malignant tumor, ranging from 18 to 80 years, Were divided into the treatment group and control group.

[Spontaneous reporting system data analysis of parenterally administered Shenmai].

Spontaneous reporting system (SRS) datais currently an important source of monitoring and finding ADRs signals throughout the world. This method can promptly and effectively discover ADR signals, thus preventing and avoiding ADRs effectively. Parenterally administered Shenmai has the functions of benefiting vital energy, nourishing Yin and generating body fluids, and activating the pulse.